Larvol Delta - Viracta-Therapeutics-Provides-an-Update-on-the-Phase-1b2-Trial-of-Nanaval-in-Patients-with-Advanced-EpsteinBarr-VirusPositive-EBV-Solid-Tumors-and-Announces-Upcoming-Poster-Presentation-at-the-ASCO-Annual-Meeting

nanatinostat (VRx-3996) - Viracta Therap

https://www.prnewswire.com/news-releases/viracta-therapeutics-provides-an-update-on-the-phase-1b2-trial-of-nana-val-in-patients-with-advanced-epstein-barr-virus-positive-ebv-solid-tumors-and-announces-upcoming-poster-presentation-at-the-asco-annual-meeting-301559805.html

Jun 2, 2022

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next